Nexelis, a portfolio company of Ampersand Capital Partners, and a provider of assay development and advanced laboratory testing has signed a definitive agreement to acquire ImmunXperts. The closing of the transaction is expected by the end of March. Based in the Brussels South Charleroi Biopark within the town of Gosselies, ImmunXperts has developed and performs a full offering of immunogenicity and immuno-oncology in vitro functional and potency assays. These assays help pharmaceutical and bio...